Digoxin Injection, CSD
... accordingly. Digoxin toxicity develops more frequently and lasts longer in patients with renal impairment because of the decreased excretion of digoxin. Therefore, it should be anticipated that dosage requirements will be decreased in patients with moderate to severe renal disease (see DOSAGE AND AD ...
... accordingly. Digoxin toxicity develops more frequently and lasts longer in patients with renal impairment because of the decreased excretion of digoxin. Therefore, it should be anticipated that dosage requirements will be decreased in patients with moderate to severe renal disease (see DOSAGE AND AD ...
[Product Monograph Template
... administration may cause an acute opioid withdrawal syndrome which may be life threatening in opioid dependent neonates if not recognized and properly treated (see WARNINGS AND PRECAUTIONS, Acute Opioid Withdrawal Syndrome). Clinical data is limited and naloxone should be administered to a neonate o ...
... administration may cause an acute opioid withdrawal syndrome which may be life threatening in opioid dependent neonates if not recognized and properly treated (see WARNINGS AND PRECAUTIONS, Acute Opioid Withdrawal Syndrome). Clinical data is limited and naloxone should be administered to a neonate o ...
MICROMEDEX® Healthcare Series OXCARBAZEPINE
... 1.4.1.A.1 Partial seizure, monotherapy a) Conversion 1) For conversion of therapy from other antiepileptic drugs (AEDs) to oxcarbazepine monotherapy in children 4 to 16 years, oxcarbazepine therapy should be initiated with a dose of 8 to 10 milligrams/kilogram/day (mg/kg/day in two divided doses; si ...
... 1.4.1.A.1 Partial seizure, monotherapy a) Conversion 1) For conversion of therapy from other antiepileptic drugs (AEDs) to oxcarbazepine monotherapy in children 4 to 16 years, oxcarbazepine therapy should be initiated with a dose of 8 to 10 milligrams/kilogram/day (mg/kg/day in two divided doses; si ...
Allergan to Acquire Naurex - McCormick School of Engineering
... being prepared for late-stage trials, which are usually needed before regulatory approval. The company also has an oral depression treatment in early-stage testing. ...
... being prepared for late-stage trials, which are usually needed before regulatory approval. The company also has an oral depression treatment in early-stage testing. ...
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1
... In a clinical trial in healthy subjects, a potent inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %. ABILIFY dose should be reduced to approximately one-half of it ...
... In a clinical trial in healthy subjects, a potent inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while Cmax was unchanged. The AUC and Cmax of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %. ABILIFY dose should be reduced to approximately one-half of it ...
A Closer Look at the Risks vs. Benefits of Kava (Piper methysticum)
... self-help treatment not generally upheld in the health system. Each treatment was evaluated for its effectiveness in reducing anxiety symptoms in generalized and specific anxiety disorders (panic attacks, phobias, OCD, PTSD). Among 108 treatments used in the study, the treatments with the best evide ...
... self-help treatment not generally upheld in the health system. Each treatment was evaluated for its effectiveness in reducing anxiety symptoms in generalized and specific anxiety disorders (panic attacks, phobias, OCD, PTSD). Among 108 treatments used in the study, the treatments with the best evide ...
Extract from Clinical Evaluation Report: Ivermectin
... Scabies is currently endemic in remote northern and central Aboriginal communities where up to 50% of children may be infested. By the age of one, up to 60% of indigenous children will have been affected by scabies. Rates of crusted scabies (the most severe form of the disease) in these communities ...
... Scabies is currently endemic in remote northern and central Aboriginal communities where up to 50% of children may be infested. By the age of one, up to 60% of indigenous children will have been affected by scabies. Rates of crusted scabies (the most severe form of the disease) in these communities ...
Makena - HCP Home Makena® (hydroxyprogesterone caproate
... Makena is a once-weekly intramuscular injection. Makena is administered by a healthcare provider via a single injection at a dose of 1 mL (250 mg) once a week (every 7 days). Makena is packaged as a single-dose, preservative-free vial and as a multi-dose vial that contains 5 weekly injections.1 Make ...
... Makena is a once-weekly intramuscular injection. Makena is administered by a healthcare provider via a single injection at a dose of 1 mL (250 mg) once a week (every 7 days). Makena is packaged as a single-dose, preservative-free vial and as a multi-dose vial that contains 5 weekly injections.1 Make ...
Synthesis and in vitro activities of a new antiviral duplex drug linking
... AZT–lipid–PFA was prepared in five steps according to the synthesis scheme given in (Fig. 1) starting with 3-O-octadecyl-snglyercol (1). In the first synthesis step the free terminal hydroxyl group of 1 was blocked with the 4-monomethoxytrityl residue. After the chromatographic purification of the reac ...
... AZT–lipid–PFA was prepared in five steps according to the synthesis scheme given in (Fig. 1) starting with 3-O-octadecyl-snglyercol (1). In the first synthesis step the free terminal hydroxyl group of 1 was blocked with the 4-monomethoxytrityl residue. After the chromatographic purification of the reac ...
Ezetimibe and rosuvastatin - Therapeutic Goods Administration (TGA)
... 183603, 183605, 183607) – sponsored by Sandoz (at the time of submission, MSD had applied to have the sponsorship of rosuvastatin transferred to MSD). ...
... 183603, 183605, 183607) – sponsored by Sandoz (at the time of submission, MSD had applied to have the sponsorship of rosuvastatin transferred to MSD). ...
The Pharmacology of Lysergic Acid Diethylamide: A Review
... been injected with doses as high as 1 mg/kg i.v. without any lasting somatic effects [55]. There have been no documented human deaths from an LSD overdose. Eight individuals who accidentally consumed a very high dose of LSD intranasally (mistaking it for cocaine) had plasma levels of 1000–7000 μg pe ...
... been injected with doses as high as 1 mg/kg i.v. without any lasting somatic effects [55]. There have been no documented human deaths from an LSD overdose. Eight individuals who accidentally consumed a very high dose of LSD intranasally (mistaking it for cocaine) had plasma levels of 1000–7000 μg pe ...
SERETIDE ACCUHALER/DISKUS™
... Diskus®) (Hazard ratio for Salmeterol + Fluticasone propionate Dry Powder for Inhalation (Seretide® Diskus®) vs placebo: 1.64, 95% CI: 1.33 to 2.01, p<0.001). There was no increase in pneumonia related deaths; deaths while on treatment that were adjudicated as primarily due to pneumonia were 7 for ...
... Diskus®) (Hazard ratio for Salmeterol + Fluticasone propionate Dry Powder for Inhalation (Seretide® Diskus®) vs placebo: 1.64, 95% CI: 1.33 to 2.01, p<0.001). There was no increase in pneumonia related deaths; deaths while on treatment that were adjudicated as primarily due to pneumonia were 7 for ...
Advair HFA - GSK Source
... Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, one of the active ingredients in ADVAIR® HFA Inhalation Aerosol, increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of salmeterol with placebo added to usual asthma therap ...
... Long-acting beta2-adrenergic agonists (LABA), such as salmeterol, one of the active ingredients in ADVAIR® HFA Inhalation Aerosol, increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of salmeterol with placebo added to usual asthma therap ...
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
... Patients receiving triamterene and hydrochlorothiazide should be carefully monitored for fluid or electrolyte imbalances, i.e., hyponatremia, hypochloremic alkalosis, hypokalemia and hypomagnesemia. Determination of serum electrolytes to detect possible electrolyte imbalance should be performed at ...
... Patients receiving triamterene and hydrochlorothiazide should be carefully monitored for fluid or electrolyte imbalances, i.e., hyponatremia, hypochloremic alkalosis, hypokalemia and hypomagnesemia. Determination of serum electrolytes to detect possible electrolyte imbalance should be performed at ...
Manuscript_12122012_revised
... concentrations, which the Phoenix assay could not detect. Samples from instillations was analysed using the Bachem EIA in order to cater for very low serum sCT concentrations, while samples following i.v. administration were analysed with the Phoenix EIA, where interrat variation was less at higher ...
... concentrations, which the Phoenix assay could not detect. Samples from instillations was analysed using the Bachem EIA in order to cater for very low serum sCT concentrations, while samples following i.v. administration were analysed with the Phoenix EIA, where interrat variation was less at higher ...
Understanding Niacin Formulations - Health-Mall
... truncal flushing, which is experienced by most patients during the initial days of treatment.6 Although symptoms diminish over time, many patients stop therapy before tolerance develops.7 Other unwanted effects include itching, mucous membrane irritation, and diarrhea. Another limitation of niacin I ...
... truncal flushing, which is experienced by most patients during the initial days of treatment.6 Although symptoms diminish over time, many patients stop therapy before tolerance develops.7 Other unwanted effects include itching, mucous membrane irritation, and diarrhea. Another limitation of niacin I ...
Drug utilisation sub-committee (DUSC)
... therapies co administered with ezetimibe products. The analyses imputed drug regimens for the prevalent treated population since ezetimibe was first available (August 2004). The methodology is fully described in Appendix C. All ezetimibe products are priced above the general patient copayment, howev ...
... therapies co administered with ezetimibe products. The analyses imputed drug regimens for the prevalent treated population since ezetimibe was first available (August 2004). The methodology is fully described in Appendix C. All ezetimibe products are priced above the general patient copayment, howev ...
A review on pharmacological property of Mimusops elengi Linn.
... have recorded significant antifungal activity against one or the other Aspergillus species tested [25]. Different solvent extracts of bark, fruits (fleshy portion) and leaves of Mimusops elengi were screened for their antifungal activity against some fungi. The bark extracts were found to be active ...
... have recorded significant antifungal activity against one or the other Aspergillus species tested [25]. Different solvent extracts of bark, fruits (fleshy portion) and leaves of Mimusops elengi were screened for their antifungal activity against some fungi. The bark extracts were found to be active ...
Full US Prescribing Information including boxed warning
... stable dosage of medication who are making progress toward their treatment objectives. Continuation or modification of pharmacotherapy should be based on the physician’s evaluation of treatment outcomes and objectives such as: 1. Absence of medication toxicity 2. Absence of medical or behavioral adv ...
... stable dosage of medication who are making progress toward their treatment objectives. Continuation or modification of pharmacotherapy should be based on the physician’s evaluation of treatment outcomes and objectives such as: 1. Absence of medication toxicity 2. Absence of medical or behavioral adv ...
Contributions of CYP3A4, P-glycoprotein, and Serum Protein
... 1999), onto which the Caco-2 cell clone P27.7 (Schmiedlin-Ren et al., 1997) (passage 22–33) was seeded at a density of ⬃5 ⫻ 105 cells/cm2. The cell cultures were maintained in complete growth medium (consisting of DMEM, 20% heat-inactivated FBS, 0.1 mM NEAA, 50 g/ml gentamicin, and 45 nM vitamin E) ...
... 1999), onto which the Caco-2 cell clone P27.7 (Schmiedlin-Ren et al., 1997) (passage 22–33) was seeded at a density of ⬃5 ⫻ 105 cells/cm2. The cell cultures were maintained in complete growth medium (consisting of DMEM, 20% heat-inactivated FBS, 0.1 mM NEAA, 50 g/ml gentamicin, and 45 nM vitamin E) ...
Piracetam: A Review of Pharmacological
... originally marketed in 1971 by UCB Pharma. It was the first “nootropic” drug (25), an agent that acts on cognitive function without causing sedation or stimulation. While the mechanisms of action of piracetam have yet to be fully elucidated, it influences neuronal and vascular functions. Furthermore ...
... originally marketed in 1971 by UCB Pharma. It was the first “nootropic” drug (25), an agent that acts on cognitive function without causing sedation or stimulation. While the mechanisms of action of piracetam have yet to be fully elucidated, it influences neuronal and vascular functions. Furthermore ...
product monograph - Eli Lilly Canada
... Signs and Symptoms: GLUCAGON (glucagon for injection, rDNA origin) is generally well tolerated. If overdosage occurred, it would not be expected to cause consequential toxicity, but would be expected to be associated with nausea, vomiting, gastric hypotonicity, and diarrhea. Intravenous administrati ...
... Signs and Symptoms: GLUCAGON (glucagon for injection, rDNA origin) is generally well tolerated. If overdosage occurred, it would not be expected to cause consequential toxicity, but would be expected to be associated with nausea, vomiting, gastric hypotonicity, and diarrhea. Intravenous administrati ...
Polyethylene Glycol: A Game-Changer Laxative for Children
... as an osmotic laxative because of its chemical properties (10). The laxative effect is achieved not only by the osmotic effect but also because of PEG’s ability to form a unique interaction with the water molecules. This interaction alters the physical chemistry of the solution, which leads to a seq ...
... as an osmotic laxative because of its chemical properties (10). The laxative effect is achieved not only by the osmotic effect but also because of PEG’s ability to form a unique interaction with the water molecules. This interaction alters the physical chemistry of the solution, which leads to a seq ...
PRODUCT MONOGRAPH Pr CLINDOXYL® ADV Gel Pr
... subjects who experienced treatment-related adverse events was low and was similar in each treatment group . No individual treatment-related adverse event was reported by more than 2 subjects (≤ 1%) within any of the treatment groups. The most frequentlyreported treatment-related adverse events were ...
... subjects who experienced treatment-related adverse events was low and was similar in each treatment group . No individual treatment-related adverse event was reported by more than 2 subjects (≤ 1%) within any of the treatment groups. The most frequentlyreported treatment-related adverse events were ...
Investigator`s Brochure - Multidisciplinary Association for
... from a safety perspective, recent studies have examined the effects of this compound on attention, prosocial effects, memory and brain activity, and human drug discrimination. Findings from an initial report indicated that MDMA-assisted psychotherapy could be conducted safely in people with chronic ...
... from a safety perspective, recent studies have examined the effects of this compound on attention, prosocial effects, memory and brain activity, and human drug discrimination. Findings from an initial report indicated that MDMA-assisted psychotherapy could be conducted safely in people with chronic ...